Xeris Biopharma reports record Q4 revenue $60M (+35% YoY); guides 2025 rev $255M-$275M

Xeris Biopharma Holdings, Inc.

Record Q4 total revenue $60.1M (+35% YoY); full-year $203.1M (+24% YoY)
Recorlev Q4 revenue $22.6M (+131% YoY); full-year $64.3M (+118% YoY)
Q4 net loss $5.1M (($0.03)/share); Adjusted EBITDA $8.3M; cash $71.6M
FY2025 revenue guidance $255M-$275M; expects positive Adjusted EBITDA going forward

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.